WO2001066083A1 - Gel preparations for oral administration having improved preservation properties - Google Patents
Gel preparations for oral administration having improved preservation properties Download PDFInfo
- Publication number
- WO2001066083A1 WO2001066083A1 PCT/JP2001/001802 JP0101802W WO0166083A1 WO 2001066083 A1 WO2001066083 A1 WO 2001066083A1 JP 0101802 W JP0101802 W JP 0101802W WO 0166083 A1 WO0166083 A1 WO 0166083A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- gel preparations
- gel
- oral gel
- patients
- properties
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Definitions
- the present invention relates to an oral gel formulation, and more particularly, to an oral gel formulation having improved preservability while taking advantage of the gel formulation.
- the gel preparation is excellent in ingestibility, it is suitably used as a preparation for elderly people, sick people, children and the like having a low swallowing ability.
- gel preparations can be easily colored and flavored to improve their visual and taste properties, and they can be taken without water, so they can be applied to products with excellent portability.
- gelling agents such as agar and carrageenan are known as gelling agents used in such gel preparations.
- carrageenan is most preferable in terms of water separation from the gel, ingestibility, and elution of the drug.
- carrageenan as a gelling agent, the present inventors adjusted pH to a range of 4 to 9, which is preferable for ensuring gel stability, blended sucrose to improve flavor, and added paraben as a preservative. Attempts to provide a gel formulation with a formulation based on drugs, the gel formulation has insufficient preservative effect, despite the fact that other dosage forms contain a sufficient amount of preservative to show a preservative effect I found something.
- the present inventors have conducted various studies to provide a gel preparation having a sufficient preservative effect without impairing the advantages of the gel preparation, and as a result, added sugar alcohol instead of sucrose used for flavor improvement, When the agent was changed to sorbic acid, it was found that a gel preparation having a sufficient preservative effect could be provided while maintaining the advantages of the gel preparation, and completed the present invention.
- the present invention is an oral gel preparation containing carrageenan, sugar alcohol and sorbic acid, and having a pH in the range of 4 to 9.
- the amount of carrageenan used in the present invention is preferably from 0.01 to 20% by mass, more preferably from 0.5 to 10% by mass, from the viewpoint of the stability of the gel preparation.
- sugar alcohols include sorbitol, xylitol, erythritol, maltitol, etc., and xylitol or erythritol is preferred from the viewpoint of flavor and stability.
- the amount of the sugar alcohol varies depending on the type of the sugar alcohol, but is preferably from 10 to 50% by mass of the whole preparation from the viewpoint of flavor.
- sorbic acid used in the present invention those usually used can be used, and salts thereof (eg, potassium salts) can also be used.
- the amount of sorbic acid is preferably from 0.01 to 0.8% by mass of the whole preparation from the viewpoint of preservability.
- the pH needs to be 4 to 9 from the viewpoint of stability of the gel, preferably 4 to 7 and more preferably 5 to 6.
- a commonly used pH adjuster can be used, but from the viewpoint of flavor, safety, preservation and the like, a combination of citric acid and sodium citrate is most preferred.
- the pH of the gel can be measured with a general pH meter.
- the preservative effect can be further improved by adding a preservative effect enhancer.
- the preservative effect enhancer is a component that helps the absorption of sorbic acid by spoilage sources such as mold, yeast, and bacteria.
- menthol, limonene, Caprylic acid, capric acid, saponins and the like can be used. Of these, menthol is particularly preferred.
- the oral gel preparation of the present invention may optionally contain orally administrable pharmaceutical ingredients, nutritional ingredients, and the like.
- flavoring agents flavors, emulsifiers, stabilizers, fillers, and the like, which can be incorporated in oral preparations, can be incorporated as additives.
- sweeteners such as stevioside and thaumatin
- flavoring agents such as cocoa powder
- surfactants such as polyglycerin fatty acid ester and sucrose fatty acid ester
- fillers such as silicon dioxide, for example, Ezrol 200 (trade name), etc. Is raised.
- components that can be blended with ordinary pharmaceuticals can be blended.
- it is preferable not to mix sucrose from the viewpoint of antiseptic properties but it is possible to mix sucrose in a small amount that can ensure antiseptic properties from the viewpoint of improving flavor.
- the oral gel preparation of the present invention dissolves water, carrageenan, sugar alcohol, and other components, if necessary, adjusts the pH, mixes by heating, and then becomes a size and a shape easy for oral administration. As described above, it can be obtained by filling in an appropriate container and solidifying by cooling.
- a powder mixture of 140 g of xylitol, 110 g of maltitol, and 14 g of carrageenan was added, and after sufficiently dispersing at room temperature, the mixture was dissolved by heating to 60 to 80, followed by quenching. After adjusting the pH to 6 by adding an appropriate amount of an acid, the mixture was filled in a predetermined container, and cooled and solidified to 30 or less to obtain a desired internal gel. Examples 2 to 5
- Example 1 The preservability of each Example and Comparative Example was evaluated by the preservative efficacy test described in Japanese Pharmacopoeia (13). Five strains (S. aureus C. albicans E. coli P. aeruginosa A.niger) were used for evaluation, and the results are shown in Tables 2 to 4 (the unit of number is log cfu / g).
- Example 1 As a result, in the composition of Example 1, the growth of the five strains used in this experiment was not observed.
- the composition of Example 1 exhibited the same preservative efficacy in S. aureus as in Comparative Example 1, and was also effective against P. aeruginosa and A. niger, which had no effect in Comparative Example 1. .
- Industrial applicability
- the gel preparation of the present invention has the advantages of conventionally known gel preparations (excellent ingestibility, ease of flavor improvement, moldability into free shapes, portability that can be taken without water). Having sufficient antiseptic properties without loss, patients with low swallowing ability (elderly, pediatric, severely ill, etc.), patients who do not like to take medicine (children, etc.) It has become possible to provide a particularly useful formulation for patients who are difficult to take.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
明細書 防腐性を向上した経口用ゲル製剤 技術分野 Description Oral gel formulation with improved antiseptic properties
本発明は経口用ゲル製剤に関し、 さらに詳しくは、 ゲル製剤の利点を生かしな がら防腐性を向上させた経口用ゲル製剤に関する。 背景技術 The present invention relates to an oral gel formulation, and more particularly, to an oral gel formulation having improved preservability while taking advantage of the gel formulation. Background art
ゲル製剤は、 服用性に優れているので、 嚥下能力が低い老人、 病人、 小児など に対する製剤に好適に用いられる。 また、 ゲル製剤は着色や風味付けが容易な事 から視覚、 味覚の面で商品性の向上を図ることができ、 さらに、 水無しで服用で きることから携帯性に優れた商品などに適用できるなど、 様々な利点がある。 この様なゲル製剤に用いるゲル化剤としては寒天類、 カラギーナンなど種々の ものが知られている。 それらのゲル化剤のうち、 ゲルからの離水、 服用性、 薬物 の溶出などの点ではカラギ一ナンが最も好ましい。 Since the gel preparation is excellent in ingestibility, it is suitably used as a preparation for elderly people, sick people, children and the like having a low swallowing ability. In addition, gel preparations can be easily colored and flavored to improve their visual and taste properties, and they can be taken without water, so they can be applied to products with excellent portability. There are various advantages. Various gelling agents such as agar and carrageenan are known as gelling agents used in such gel preparations. Among these gelling agents, carrageenan is most preferable in terms of water separation from the gel, ingestibility, and elution of the drug.
一般的に、 医薬品、 食品などはその品質の確保が重要であり、 特に腐敗防止は 極めて重要である。 腐敗防止のためには、 通常パラォキシ安息香酸エステル類な どの防腐剤を配合している。 In general, it is important to ensure the quality of pharmaceuticals and foods, and it is especially important to prevent corruption. To prevent spoilage, preservatives such as paraoxybenzoates are usually added.
従来、 ゲル製剤としては特開昭 5 6 - 9 7 2 2 0号公報、 特開平 6 - 2 5 6 2 2 1号公報に記載された技術などが知られているが、 ゲル製剤の防腐性に着目し た技術は知られていない。 発明の開示 Conventionally, as gel preparations, the techniques described in JP-A-56-97220 and JP-A-6-256221 are known. The technology that focuses on is not known. Disclosure of the invention
本発明者らは、 ゲル化剤にカラギーナンを用いて、 p Hをゲルの安定性確保に 好ましい 4〜9の範囲に調節し、 風味改善のためにショ糖を配合し、 防腐剤とし てパラベン類を用いた処方でゲル製剤の提供を試みたところ、 他の剤形では十分 な防腐効果を示す量の防腐剤を配合しているのにも拘わらず、 ゲル製剤では防腐 効果が不十分であることを見出した。 本発明者らは、 ゲル製剤の利点を損なうことなく、 十分な防腐効果を持ったゲ ル製剤を提供するために種々検討した結果、 風味改善に用いるショ糖の代わりに 糖アルコールを加え、 防腐剤をソルビン酸に変更すると、 ゲル製剤の利点はその ままに、 十分な防腐効果を兼ね備えたゲル製剤が提供できることを見出し本発明 を完成した。 Using carrageenan as a gelling agent, the present inventors adjusted pH to a range of 4 to 9, which is preferable for ensuring gel stability, blended sucrose to improve flavor, and added paraben as a preservative. Attempts to provide a gel formulation with a formulation based on drugs, the gel formulation has insufficient preservative effect, despite the fact that other dosage forms contain a sufficient amount of preservative to show a preservative effect I found something. The present inventors have conducted various studies to provide a gel preparation having a sufficient preservative effect without impairing the advantages of the gel preparation, and as a result, added sugar alcohol instead of sucrose used for flavor improvement, When the agent was changed to sorbic acid, it was found that a gel preparation having a sufficient preservative effect could be provided while maintaining the advantages of the gel preparation, and completed the present invention.
すなわち本発明はカラギーナン、 糖アルコールおよびソルビン酸を配合し、 p Hが 4〜 9の範囲である経口用ゲル製剤である。 発明を実施するための最良の形態 That is, the present invention is an oral gel preparation containing carrageenan, sugar alcohol and sorbic acid, and having a pH in the range of 4 to 9. BEST MODE FOR CARRYING OUT THE INVENTION
本発明に用いられるカラギーナンの配合量は、 ゲル製剤の安定性の点から製剤 全体の 0 . 0 1〜2 0質量%が好ましく、 0 . 5〜 1 0質量%がさらに好ましい。 本発明で糖アルコールとは、 ソルビトール、 キシリ トール、 エリスリ トール、 マルチトールなどであるが、 風味および安定性の点からキシリ トールまたはエリ スリ トールが好ましい。 The amount of carrageenan used in the present invention is preferably from 0.01 to 20% by mass, more preferably from 0.5 to 10% by mass, from the viewpoint of the stability of the gel preparation. In the present invention, sugar alcohols include sorbitol, xylitol, erythritol, maltitol, etc., and xylitol or erythritol is preferred from the viewpoint of flavor and stability.
糖アルコールの配合量は、 糖アルコールの種類によって異なるが、 風味の点か ら製剤全体の 1 0〜 5 0質量%が好ましい。 The amount of the sugar alcohol varies depending on the type of the sugar alcohol, but is preferably from 10 to 50% by mass of the whole preparation from the viewpoint of flavor.
本発明で用いるソルビン酸は通常使用されるものを使用することができ、 その 塩 (カリウム塩など) を使用することもできる。 As the sorbic acid used in the present invention, those usually used can be used, and salts thereof (eg, potassium salts) can also be used.
ソルビン酸の配合量は防腐性の点から製剤全体の 0 . 0 1〜0 . 8質量%が好 ましい。 The amount of sorbic acid is preferably from 0.01 to 0.8% by mass of the whole preparation from the viewpoint of preservability.
本発明ではゲルの安定性の点から p H 4〜 9である必要があり、 p H 4〜 7が 好ましく、 p H 5〜6がさらに好ましい。 p Hの調節には通常用いられる p H調 節剤を使用することができるが、 風味、 安全性、 防腐性などの点からクェン酸お よびクェン酸ナトリウムの組合せが最も好ましい。 なお、 ゲル剤の p H測定は一 般的な p H測定器で測定することができる。 In the present invention, the pH needs to be 4 to 9 from the viewpoint of stability of the gel, preferably 4 to 7 and more preferably 5 to 6. For adjusting pH, a commonly used pH adjuster can be used, but from the viewpoint of flavor, safety, preservation and the like, a combination of citric acid and sodium citrate is most preferred. The pH of the gel can be measured with a general pH meter.
本発明ではさらに防腐効果増強剤を配合することにより防腐効果をさらに向上 させることができる。 ここで防腐効果増強剤とはカビ、 酵母、 細菌などの腐敗源 が、 ソルビン酸の吸収を補助する成分であり、 具体的にはメントール、 リモネン、 力プリル酸、 力プリン酸、 サポニン類などを用いることができる。 それらの中で も特にメントールが好ましい。 In the present invention, the preservative effect can be further improved by adding a preservative effect enhancer. Here, the preservative effect enhancer is a component that helps the absorption of sorbic acid by spoilage sources such as mold, yeast, and bacteria. Specifically, menthol, limonene, Caprylic acid, capric acid, saponins and the like can be used. Of these, menthol is particularly preferred.
本発明の経口ゲル製剤には必要に応じて経口投与可能な医薬成分、 栄養成分な どを配合することができる。 The oral gel preparation of the present invention may optionally contain orally administrable pharmaceutical ingredients, nutritional ingredients, and the like.
本発明には添加物として、 経口製剤に配合可能な矯味剤、 香料、 乳化剤、 安定 化剤、 充填剤、 などを配合することができる。 例えば、 ステビオシド、 ソーマチ ンなどの甘味剤、 ココア末などの矯味剤、 ポリグリセリン脂肪酸エステル、 ショ 糖脂肪酸エステルなどの界面活性剤、 二酸化ケイ素、 例えばエロジール 2 0 0 (商品名) などの充填剤などがあげられる。 またこれら添加物以外にも、 必要に 応じて、 通常の医薬品に配合可能な成分を配合することができる。 なお、 防腐性 の点からは、 ショ糖は配合しない方が好ましいが、 風味改善の点から防腐性を確 保できる少量であれば配合も可能である。 In the present invention, flavoring agents, flavors, emulsifiers, stabilizers, fillers, and the like, which can be incorporated in oral preparations, can be incorporated as additives. For example, sweeteners such as stevioside and thaumatin, flavoring agents such as cocoa powder, surfactants such as polyglycerin fatty acid ester and sucrose fatty acid ester, and fillers such as silicon dioxide, for example, Ezrol 200 (trade name), etc. Is raised. In addition to these additives, if necessary, components that can be blended with ordinary pharmaceuticals can be blended. In addition, it is preferable not to mix sucrose from the viewpoint of antiseptic properties, but it is possible to mix sucrose in a small amount that can ensure antiseptic properties from the viewpoint of improving flavor.
本発明の経口用ゲル製剤は、 水、 カラギーナン、 糖アルコール、 必要で有れば その他の成分を溶解させ、 p Hを調節し、 加温混合させた後、 経口容易な大きさ 及び形状となるように適当な容器中に充填して冷却固化することにより得ること ができる。 実施例 The oral gel preparation of the present invention dissolves water, carrageenan, sugar alcohol, and other components, if necessary, adjusts the pH, mixes by heating, and then becomes a size and a shape easy for oral administration. As described above, it can be obtained by filling in an appropriate container and solidifying by cooling. Example
以下、 実施例および試験例により本発明をさらに詳細に説明する。 Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples.
実施例 1 Example 1
ピコスルフアートナトリウム 0 . 2 5 g、 クェン酸 0 . 2 g、 クェン酸ナトリ ゥム 4 . 8 g、 メントール 1 2 g、 ソルビン酸カリウム 1 gを精製水 7 2 9 · 8 3 gに溶解した。 0.25 g of sodium picosulfate, 0.2 g of citrate, 4.8 g of sodium citrate, 12 g of menthol, and 1 g of potassium sorbate were dissolved in 729,83 g of purified water .
これに、 別にキシリ トール 1 4 0 g、 マルチトール 1 1 0 g、 カラギーナン 1 4 gを混合した粉体を加え、 室温で十分分散した後 6 0〜 8 0 に加熱して溶解 し、 さらにクェン酸を適量加えて p H 6に調整した後、 所定の容器に充填し、 3 0 以下に冷却成形固化して目的の内服ゲルを得た。 実施例 2〜 5 Separately, a powder mixture of 140 g of xylitol, 110 g of maltitol, and 14 g of carrageenan was added, and after sufficiently dispersing at room temperature, the mixture was dissolved by heating to 60 to 80, followed by quenching. After adjusting the pH to 6 by adding an appropriate amount of an acid, the mixture was filled in a predetermined container, and cooled and solidified to 30 or less to obtain a desired internal gel. Examples 2 to 5
表 1に示した成分について実施例 1と同様の方法で内服ゲル製剤を調製した, 比較例 1 An oral gel preparation was prepared for the components shown in Table 1 in the same manner as in Example 1, Comparative Example 1
ピコスルフアートナトリウム 0. 2 5 g、 クェン酸 0. 2 g、 クェン酸ナトリ ゥム 4. 8 g、 プロピルパラベン 0. 2 g、 ブチルパラベン 0. 06 7 g、 安息 香酸ナトリウム 3 gを精製水 727. 683 gに溶解した。 これに、 別に砂糖 2 50 g、 カラギーナン 14 gを混合した粉体を加え、 室温で十分分散した後 60 〜 80 に加熱して溶解し、 さらにクェン酸を適量加えて pH 6に調整した後、 所定の容器に充填し、 30で以下に冷却成形固化して目的の内服ゲルを得た。 Purify 0.25 g of sodium picosulfate, 0.2 g of citrate, 4.8 g of sodium citrate, 0.2 g of propylparaben, 0.07 g of butylparaben, and 3 g of sodium benzoate Dissolved in 727.683 g of water. Separately, powder mixed with 250 g of sugar and 14 g of carrageenan was added, dispersed sufficiently at room temperature, dissolved by heating to 60 to 80, and adjusted to pH 6 by adding an appropriate amount of citric acid. The mixture was filled in a predetermined container, and cooled and solidified in the following at 30 to obtain a target oral gel.
表 1 table 1
試験例 Test example
各実施例及び比較例の防腐性を日本薬局方 ( 1 3) 記載の保存効力試験により 5菌株 (S. aureus C. albicans E.coli P. aeruginosa A.niger) を用 評価した, 結果を表 2〜4に示した (数字の単位は log cfu/g) 。 The preservability of each Example and Comparative Example was evaluated by the preservative efficacy test described in Japanese Pharmacopoeia (13). Five strains (S. aureus C. albicans E. coli P. aeruginosa A.niger) were used for evaluation, and the results are shown in Tables 2 to 4 (the unit of number is log cfu / g).
表 2 Table 2
表 3 Table 3
表 4 Table 4
その結果、 実施例 1の組成物では、 今回用いた 5菌株の増殖は認められなかつ た。 実施例 1の組成物は、 S. aureusにおいては比較例 1と同等の保存効力を示し, さらに比較例 1では効果のなかった P. aeruginosaや A.nigerに対しても効果が認 められた。 産業上の利用可能性 As a result, in the composition of Example 1, the growth of the five strains used in this experiment was not observed. The composition of Example 1 exhibited the same preservative efficacy in S. aureus as in Comparative Example 1, and was also effective against P. aeruginosa and A. niger, which had no effect in Comparative Example 1. . Industrial applicability
本発明のゲル製剤は、 従来から知られているゲル製剤の利点 (優れた服用性、 風味改善の容易性、 自由な形状への成形性、 水不要で服用できる携帯性など) を 損なうことなく十分な防腐性も持ち合わせていることから、 嚥下能力の低い患者 (老人、 小児、 重病者など) 、 薬の服用を好まない患者 (小児など) 、 外出が多 いなどから水と同時服用が困難な患者などに特に有用な製剤を提供することが可 能になった。 The gel preparation of the present invention has the advantages of conventionally known gel preparations (excellent ingestibility, ease of flavor improvement, moldability into free shapes, portability that can be taken without water). Having sufficient antiseptic properties without loss, patients with low swallowing ability (elderly, pediatric, severely ill, etc.), patients who do not like to take medicine (children, etc.) It has become possible to provide a particularly useful formulation for patients who are difficult to take.
Claims
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2001241060A AU2001241060A1 (en) | 2000-03-10 | 2001-03-08 | Gel preparations for oral administration having improved preservation properties |
| JP2001564736A JP5070669B2 (en) | 2000-03-10 | 2001-03-08 | Oral gel preparation with improved antiseptic properties |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2000067260 | 2000-03-10 | ||
| JP2000-67260 | 2000-03-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2001066083A1 true WO2001066083A1 (en) | 2001-09-13 |
Family
ID=18586488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2001/001802 Ceased WO2001066083A1 (en) | 2000-03-10 | 2001-03-08 | Gel preparations for oral administration having improved preservation properties |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JP5070669B2 (en) |
| AU (1) | AU2001241060A1 (en) |
| WO (1) | WO2001066083A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005025622A1 (en) * | 2003-09-12 | 2005-03-24 | Ryukakusan Co. Ltd. | Bitterness-masking particulate jelly beverage |
| WO2006006595A1 (en) * | 2004-07-12 | 2006-01-19 | Teikokumedix Co., Ltd. | Medicinal composition for oral use |
| JP2008094743A (en) * | 2006-10-10 | 2008-04-24 | Tohoku Techno Arch Co Ltd | Food for improving eating and swallowing |
| WO2017031121A1 (en) * | 2015-08-17 | 2017-02-23 | Liang Alfred Chi-Yeh | Liquid formulations containing picosulfate and magnesium citrate |
| US10624879B2 (en) | 2014-03-19 | 2020-04-21 | Ferring International Center S.A. | Liquid pharmaceutical composition |
| US12458634B2 (en) | 2016-07-08 | 2025-11-04 | Ferring B.V. | Stabilized liquid formations containing picosulfate |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10236983A (en) * | 1997-02-25 | 1998-09-08 | Taisho Pharmaceut Co Ltd | Gel-like sustained release composition |
| JPH1192402A (en) * | 1997-07-24 | 1999-04-06 | Eisai Co Ltd | Formulation composition and its production |
| JPH11322606A (en) * | 1998-05-14 | 1999-11-24 | Kobayashi Seiyaku Kogyo Kk | Readily swallowable anti-malignant tumor preparation |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0312231A (en) * | 1989-06-09 | 1991-01-21 | Kotobuki Akad:Kk | Capsule film composition |
| JP3009531B2 (en) * | 1992-03-30 | 2000-02-14 | サンスター株式会社 | Periodontal disease prevention agent |
| JPH06253741A (en) * | 1993-03-03 | 1994-09-13 | Honsyu Kosan Kk | Antimicrobial throat candy |
| JP4309481B2 (en) * | 1996-01-12 | 2009-08-05 | テイコクメディックス株式会社 | Jelly oral pharmaceutical composition |
| JP3257983B2 (en) * | 1997-07-31 | 2002-02-18 | 株式会社龍角散 | Drug swallowing aid drink |
| JP3651544B2 (en) * | 1997-08-29 | 2005-05-25 | ライオン株式会社 | Salivary secretion promoter and composition for oral cavity |
| JPH11180864A (en) * | 1997-12-19 | 1999-07-06 | Nippon Chemiphar Co Ltd | Jelly preparation containing alkali citrate |
| JPH11271694A (en) * | 1998-03-24 | 1999-10-08 | Nippon Tenganyaku Kenkyusho:Kk | Cleaning solution for contact lenses |
-
2001
- 2001-03-08 WO PCT/JP2001/001802 patent/WO2001066083A1/en not_active Ceased
- 2001-03-08 AU AU2001241060A patent/AU2001241060A1/en not_active Abandoned
- 2001-03-08 JP JP2001564736A patent/JP5070669B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10236983A (en) * | 1997-02-25 | 1998-09-08 | Taisho Pharmaceut Co Ltd | Gel-like sustained release composition |
| JPH1192402A (en) * | 1997-07-24 | 1999-04-06 | Eisai Co Ltd | Formulation composition and its production |
| JPH11322606A (en) * | 1998-05-14 | 1999-11-24 | Kobayashi Seiyaku Kogyo Kk | Readily swallowable anti-malignant tumor preparation |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8287897B2 (en) | 2003-09-12 | 2012-10-16 | Ryukakusan Co., Ltd. | Bitterness-masking particulate jelly beverage |
| JPWO2005025622A1 (en) * | 2003-09-12 | 2006-11-16 | 株式会社龍角散 | Bitter masking granular jelly beverage |
| WO2005025622A1 (en) * | 2003-09-12 | 2005-03-24 | Ryukakusan Co. Ltd. | Bitterness-masking particulate jelly beverage |
| AU2004271853B2 (en) * | 2003-09-12 | 2009-03-12 | Ryukakusan Co. Ltd. | Granular jelly drink capable of masking bitter |
| JP4647493B2 (en) * | 2003-09-12 | 2011-03-09 | 株式会社龍角散 | Bitter masking granular jelly beverage |
| WO2006006595A1 (en) * | 2004-07-12 | 2006-01-19 | Teikokumedix Co., Ltd. | Medicinal composition for oral use |
| JP2008094743A (en) * | 2006-10-10 | 2008-04-24 | Tohoku Techno Arch Co Ltd | Food for improving eating and swallowing |
| US10624879B2 (en) | 2014-03-19 | 2020-04-21 | Ferring International Center S.A. | Liquid pharmaceutical composition |
| US11191753B2 (en) | 2014-03-19 | 2021-12-07 | Ferring International Center Sa. | Liquid pharmaceutical composition |
| WO2017031121A1 (en) * | 2015-08-17 | 2017-02-23 | Liang Alfred Chi-Yeh | Liquid formulations containing picosulfate and magnesium citrate |
| CN109310774A (en) * | 2015-08-17 | 2019-02-05 | 费林股份公司 | Containing can sulfate and magnesium citrate liquid preparation |
| US11612592B2 (en) | 2015-08-17 | 2023-03-28 | Ferring B.V. | Liquid formulations containing picosulfate and magnesium citrate |
| US12458634B2 (en) | 2016-07-08 | 2025-11-04 | Ferring B.V. | Stabilized liquid formations containing picosulfate |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2001241060A1 (en) | 2001-09-17 |
| JP5070669B2 (en) | 2012-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8287897B2 (en) | Bitterness-masking particulate jelly beverage | |
| JP2874967B2 (en) | Pharmaceutical water suspension for drug actives essentially insoluble in water | |
| EP1438026B1 (en) | Taste masking spill-resistant formulation | |
| JP4051717B2 (en) | Biotin-containing oral solution | |
| US9314428B2 (en) | Oral composition comprising a cooling agent | |
| JP2001226293A (en) | Dosage aid | |
| JP5070669B2 (en) | Oral gel preparation with improved antiseptic properties | |
| US20120022104A1 (en) | Pectin-containing jelly formulation | |
| JP2002193839A (en) | Cocoa pharmaceutical preparation | |
| JP2004161679A (en) | Liquid for internal use | |
| US9364428B2 (en) | Herb medicine composition in the form of jelly | |
| JPWO2001066083A1 (en) | Oral gel formulation with improved preservative properties | |
| JP4461689B2 (en) | Jelly preparation | |
| KR101326397B1 (en) | Liquid medicine for internal use | |
| JPWO2006001344A1 (en) | Isosorbide-containing jelly preparation | |
| JP4959864B2 (en) | Glutamate-containing solution | |
| US9125809B2 (en) | Pectin-containing jelly formulation | |
| KR20150003898A (en) | Oral formulation | |
| EP3678498B1 (en) | Composition for calcium supplementation | |
| JP2003183162A (en) | Cimetidine oral preparation | |
| JP2008094743A (en) | Food for improving eating and swallowing | |
| JP7394295B2 (en) | Candy formulation and method for manufacturing candy formulation | |
| JP2003342186A (en) | Oral liquid composition for rhinitis | |
| JPS63313734A (en) | syrup | |
| JP2001106641A (en) | Intraoral medicine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 564736 Kind code of ref document: A Format of ref document f/p: F |
|
| 122 | Ep: pct application non-entry in european phase |